Table 1.

Sample characteristics

	Total	SGA exposed cohort	AD exposed cohort	p
N	284,234	31,207	253,027
Age, years±SD	44.46±10.74	44.91±11.16	44.40±10.69	<0.0001
Males, N (%)	83,606 (29.41)	10,224 (32.76)	73,382 (29.00)	<0.0001
Number of medical disorders at baseline, median (Q1, Q3)	5.00 (2.00, 9.00)	7.00 (3.00, 12.00)	5.00 (2.00, 9.00)
Patient years of follow-up censoring patients 365 days after treatment discontinuation, median (Q1, Q3)	1.49 (1.00, 2.62)	1.55 (1.00, 2.87)	1.48 (1.00, 2.59)	<0.0001
Patient years of follow-up not censoring patients 365 days after treatment discontinuation, median (Q1, Q3)	2.55 (1.62, 3.36)	2.63 (1.62, 3.55)	2.54 (1.62, 3.34)	0.0001
Patient days of treatment exposure, median (Q1, Q3)	180 (60, 480)	150 (60, 420)	180 (60, 480)	<0.0001
Mood disorders diagnosis, N (%)	60,906 (21.43)	22,681 (72.68)	38,225 (15.11)	<0.0001
Schizophrenia diagnosis, N (%)	2,027 (0.71)	1,842 (5.90)	185 (0.07)	<0.0001
SGAs prescribed during the study, N (%)
Aripiprazole		7,316 (2.57)
Asenapine		8 (0.00)
Clozapine		60 (0.02)
Olanzapine		2,901 (1.02)
Quetiapine		12,094 (4.25)
Risperidone		3,362 (1.18)
Ziprasidone		1,469 (0.52)
Mixed SGA group (see text)		3,997 (1.41)

SGA – second-generation antipsychotic, AD – antidepressant, Q1 – quartile 1, Q3 – quartile 3